Tc 99m P215

Drug Profile

Tc 99m P215

Alternative Names: P215

Latest Information Update: 11 Sep 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer Schering Pharma
  • Class Organotechnetium compounds; Peptide diagnostics; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Technetium compounds
  • Mechanism of Action Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Atherosclerosis

Most Recent Events

  • 11 Sep 2006 Discontinued - Phase-II for Atherosclerosis diagnosis in USA (unspecified route)
  • 09 Oct 2001 No development reported - Phase-II for Atherosclerosis diagnosis in USA (unspecified route)
  • 16 Nov 1999 Diatide has been acquired by Schering AG
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top